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A B S T R A C T
The dynamics of SCCVII transplantable tumor growth in C3H/H mice was determined after local tumor irradiation
and/or virus (NDV LaSota) i.p. injection. The virus applied alone significantly suppressed tumor growth, particularly
until the 19th day after tumor transplantation. Local irradiation with 30 Gy resulted in tumor disappearance followed
with its regrowth about 15 days later. However, if the virus was injected after the irradiation, there was no tumor growth
until the end of the 31 day observation period. It should be noted that virus application prior to local irradiation did not
have any additional influence on tumor growth. Thus, the pronounced efficacy of virus applied after tumor irradiation
deserves attention. It is possible that the virus injected after irradiation induced a chain of cytokine production joining
the action of tumor destruction induced by irradiation. This should be further studied in clarifying the approaches to
combined tumor therapy with possible cell-free vaccine production.
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Introduction
The problem of tumor growth control is still an open
question. Numerous approaches were attempted and
some of them are still in clinical practice, as surgery, ra-
diotherapy and chemotherapy. However, besides their
antitumor action, a pronounced detrimental effects on
normal tissue were observed. The larger the dose (or
»radical« surgery), the better control of tumor was achie-
ved, yet also the more pronounced destruction of normal
structures. So, the combination of these classical ap-
proaches involving lowered doses is the basis of numer-
ous protocols in treating tumorous patients.
Besides the above mentioned classical treatments sev-
eral others were tested in experimental models and then
in clinical approaches. One of them is the application of a
particular virus as a single anticancer agent. Several
oncolytic viruses have been identified that selectively at-
tack cancer cells but spare normal cells. Some of these vi-
ruses, classified as natural tumor selective viruses (e.g.,
Newcastle disease virus, some strains of reoviruses, ve-
sicular stomatitis virus and parvovirus), are used with-
out any genetic manipulation in cancer treatment1–5.
Others are genetically modified (e.g., herpes simplex vi-
rus type 1 and adenovirus) to increase selectivity and to
mediate oncolytic effects in animal models and in human
clinical trials6–9.
Newcastle disease virus (NDV), an avian paramyxo-
virus, is classified as a virus with inherent oncolytic ac-
tivity. NDV strains have been shown to directly destroy
different cancer cells in vitro while being significantly
less aggressive toward normal cells10,11. Preclinical data
also suggested that NDV may enhance both T-cell spe-
cific antitumor immunity and tumor nonspecific immu-
nity possibly either through induction of cytokines such
as tumor necrosis factor (TNF), interferon, IL-1, IL-6
and TNF related apoptosis inducing ligand (TRAIL), or
through the activation of tumoricidal macrophages12,13.
Even though there are many studies dealing with the
oncolytic properties of NDV as a single anticancer agent,
no studies have been carried out on the simultaneous use
of NDV and classical approach in cancer treatment such
as radiotherapy. So, this study is designed to evaluate a
multimodal cancer therapy approach utilizing a natu-
rally attenuated strain of NDV, LaSota strain, in combi-
nation with radiotherapy in an animal tumor model.
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Materials and Methods
Animals
Male mice of C3H/H strain were used in the experi-
ments. The animals were about 3 months old and weighed
20–23 g. They were provided standard diet (Mucedola, It-
aly) and tap water ad libitum. The light regime was natu-
ral. Animals were treated according to the Animal Wel-
fare Regulations.
Virus
An apathogenic strain of Newcastle disease virus,
LaSota strain, (hereinafter LS) was used in the study.
The virus was cultivated in the allantois fluid of fertil-
ized ten-day old SPF (Specific Pathogen Free) chicken
eggs. Allantois fluid was collected and EID50 was deter-
mined. Virus titre was adjusted on 109 EID50/ml allantois
fluid and subsequently allantois fluid was lyophilized.
(Pestikal LaSota spf; Veterina d.o.o, Zagreb, Croatia).
Tumor treatment
C3H/H mice were subcutaneously injected into the
right thigh with 5  105 SCCVII mouse carcinoma cells in
100 L RPMI using a tuberculin syringe and a 25- gauge
needle. Eight days later, when the tumors were 5–7 mm
in diameter, particular tumor treatments were perfor-
med. In the first experiment, tumors were irradiated
with 6 Gy and LaSota virus (5  108 EID50/mouse) was
applied 24 and 48 hours after the irradiation. In the sec-
ond experiment, tumors were irradiated with 10, 20, and
30 Gy, respectively and LaSota virus (1  109 EID50/
mouse) was injected intra peritoneally in all mice, either
24 hours prior to or 24 hours after local tumor irradia-
tion. The control group received in the same way 100 L
of saline. Tumor growth dynamics was followed by mea-
suring three tumor diameters (a,b,c) with a caliper
(Lange Skin fold Caliper, Cambridge Scientific Industry,
USA) starting on day 10 after inoculation, and subse-
quently on every 2nd or 3rd day until day 31. Tumor vol-
ume was calculated by using the formula a  b  c 
0.526.
Irradiation
Mouse right thigh (with growing tumor) was irradi-
ated by using linear accelerator Varian Clinac 1800 with
a 20 MeV electron beam, dose rate 2 Gy/min at room tem-
perature. The other leg was protected with lead blocks.
Homogeneous tumor irradiation was obtained by using 1
cm bolus.
Statistical analysis
The differences between effects of particular treat-
ments were statistically evaluated by an unpaired Stu-
dent t-test. This test was performed using a standard sta-
tistical package, STATISTICA for Windows.
Results
C3H/H mice were injected with squamous cell carci-
noma (SCCVII) cells into the right thigh.
Tumor irradiation with 6 Gy followed with two LS in-
jections
Preliminary experiment included local tumor irradia-
tion with the dose of 6 Gy followed by i.p. LS injections
(5  108 EID50/mouse) 24 and 48 hours later. As pre-
sented in Figure 1, irradiation with 6 Gy significantly
postponed tumor growth (p<0.01) during the observa-
tion period (27 days), and the addition of LS was even
more effective. In comparison to irradiation only, the dif-
ferences were significant (p<0.01) between days 12 and
21 after tumor transplantation. LS virus applied alone
significantly influenced tumor growth, especially until
day 19 after tumor transplantation.
In the following experiments, local irradiation dose
was increased (10, 20 and 30 Gy respectively) and virus
was injected as a single dose (1  109 EID50/mouse) eigher
24 hours prior to, or 24 hours after irradiation.
Tumor irradiation with 10 Gy and/or
LS injection
As presented in Figures 2a and 2b, tumor growth was
slightly postponed following 10 Gy application (p< 0.01)
between days 22 and 31 after tumor transplantation, but
not if LS was applied alone. LS injection prior to 10 Gy ir-
radiation (Figure 2a) did not additionally influence tu-
mor growth rate. However, in comparison with the irra-
diation only, the addition of LS after the irradiation
caused a significant reduction in tumor growth (p<0.05)
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Fig. 1. The influence of local tumor irradiation and LaSota virus
application on the growth of SCCVII mouse carcinoma trans-
planted in C3H/H mice. LaSota virus (5  108 EID50/ mouse)
was injected 24 and 48 hours after local tumor irradiation with
the dose of 6 Gy. The irradiation was performed at day 8 after tu-
mor transplantation.
between days 15 and 24 after tumor transplantation
(Figure 2b).
Tumor irradiation with 20 Gy and/or
LS injection
Tumor irradiation with 20 Gy significantly (p<
0.0001) suppressed its growth, as presented in Figures 3a
and 3b. During the first week after the treatment there
were no signs of tumor growth, which was followed by an
increase in tumor growth rate, but less pronounced than
in the controls. The application of LS either prior to (Fig-
ure 3a) or after the irradiation (Figure 3b) did not addi-
tionally affect tumor growth.
Tumor irradiation with 30 Gy and/or
LS injection
As presented in Figures 4a and 4b, tumor growth was
significantly suppressed (p<0.0001) during approxi-
mately two weeks after the treatment. Tumor re-growth
was noticed later except in the mice treated with LS fol-
lowing tumor irradiation (Figure 4b). Only in this group
of animals was tumor growth completely controlled until
the end of the observation period (day 31).
Discussion
Numerous data point to beneficial effects of local tu-
mor irradiation as more useful with the increase in the
irradiation dose14. However, normal surrounding tissue
is damaged too, limiting the dose of irradiation of the
tumor14. So, combined approaches, sufficiently detrimen-
tal to tumor but sparing normal tissues, are the choice in
a successful treatment15. Currently there is a satisfactory
choice of protocols for a particular tumor, but also a per-
manent need to improve their efficiency. On the other
hand, particular viruses were shown to destroy selec-
tively tumor cells in vitro11. Further, the use of virus vac-
cines was beneficial in particular clinical approaches3,4,9.
Besides direct destruction of tumor cells, as was
shown in the cultures, virus induced modification of host
immune reaction against the tumor seems to be impor-
tant. It is well known that the key steps in the generation
of an immune response to tumor cells include the loading
of tumor antigens onto antigen presenting cells, present-



























































Days after tumor cell inoculation
Fig. 2. The influence of local tumor irradiation and LaSota virus
application on the growth of SCCVII mouse carcinoma trans-
planted in C3H/H mice. Tumors were irradiated with the dose of
10 Gy and LaSota virus (1  109 EID50/mouse) was injected


























































Days after tumor cell inoculation
Fig. 3. The influence of local tumor irradiation and LaSota virus
application on the growth of SCCVII mouse carcinoma trans-
planted in C3H/H mice. Tumors were irradiated with the dose of
20 Gy and LaSota virus (1  109 EID50/mouse) was injected
either 24 hours prior to (a) or 24 hours after (b) the irradiation.
ing the antigen in an appropriate immune stimulatory
environment, activating cytotoxic lymphocytes and block-
ing autoregulatory control mechanisms16,17.
Numerous imunologically active vaccines usually re-
quire costly and laborious ex vivo cellular cultures,
whereas cell-free vaccines that can be directly adminis-
tered from an easily stored and transported vials are usu-
ally less immunologycally active but more suitable for
widespread clinical testing18.
The pronounced efficacy of viruses applied after tu-
mor irradiation deserves particular attention. It is con-
sidered that virus stimulates TNF related apoptosis by
inducing ligand – TRAIL12,19, which can lead to cell de-
struction. Further, virus induces the production of par-
ticular cytokines (IL-1, IL-6, TNF, INF , INF )20,21,
leading to NF kappa B expression22. However, the cells
expressing kappa B were shown to be more resistant to
irradiation, which might be the explanation for elimina-
tion of destructing effect of irradiation if virus had been
injected previously23.
According to the data of Raju et al.24,25, the production
of NF kappa B was increased in irradiated tissue (tumor)
about 2 hours after irradiation. It was followed by a re-
turn to the basal level about 8 hours after irradiation24,25
and, if the irradiation was repeated, there was no increase
in NF kappa B dynamics.
However, the virus injected i.p. after tumor irradia-
tion might induce cytokine production, joining the action
of tumor destruction induced by previous irradiation. By
increasing irradiation dose, tumor destruction is more
pronounced and additional application of virus (pene-
trating better in the cells damaged by irradiation!?) is
also more effective. The time schedule of LS injection fol-
lowing irradiation seems to be detrimental and should be
further studied in this model, particularly by using frac-
tionated irradiation. Is it possible that virus stimulates
the attraction of antigen presenting cells in tumor that is
being destroyed after irradiation? In the case of positive
answer this could be one of new advances in cancer vac-
cine productions. These approaches require a more pre-
cise knowledge of the generation of cellular immune re-
sponse to tumor antigens, together with the current
ability to closely monitor cellular immune response26,27.
This will likely provide powerful cell-free vaccine in the
near future.
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Days after tumor cell inoculation
Fig. 4. The influence of local tumor irradiation and LaSota virus
application on the growth of SCCVII mouse carcinoma trans-
planted in C3H/H mice. Tumors were irradiated with the dose of
30 Gy and LaSota virus (1  109 EID50/mouse) was injected
either 24 hours prior to (a) or 24 hours after (b) the irradiation.
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KOMBINIRANO DJELOVANJE VIRUSA I LOKALNOG ZRA^ENJA NA RAST TUMORA U MI[EVA
S A @ E T A K
Pra}ena je dinamika rasta karcinoma SCCVII presa|enog u mi{eve soja C3H/H nakon lokalnog zra~enja tumora i/ili
intraperitonejske (i.p.) primjene virusa. Primjena samog virusa zna~ajno je usporila rast tumora do 19. dana nakon
ubrizgavanja tumorskih stanica. Lokalno zra~enje tumora dozom od 30 Gy rezultira nestankom tumora do 15. dana,
nakon ~ega je uslijedio njegov ponovni rast. Me|utim, ako je virus primijenjen nakon zra~enja tumorski rast nije za-
bilje`en do 31. dana kada je eksperiment zavr{en. Primije}eno je da virus primijenjen prije lokalnog zra~enja tumora
nema dodatni utjecaj na rast tumora. Ova jasno izra`ena u~inkovitost primjene virusa nakon lokalnog zra~enja tumora
zaslu`uje pozornost. Mogu}e je da virus primijenjen nakon zra~enja inducira produkciju citokina koji poma`u destruk-
ciju tumora induciranu zra~enjem. Ovo bi trebalo nadalje razraditi u kombiniranim terapijskim pristupima.
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